<DOC>
	<DOCNO>NCT00022451</DOCNO>
	<brief_summary>RATIONALE : Tipifarnib may stop growth cancer cell block enzymes necessary cancer cell growth . PURPOSE : Phase I trial study effectiveness tipifarnib treat young patient refractory leukemia .</brief_summary>
	<brief_title>Tipifarnib Treating Young Patients With Refractory Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose toxicity profile tipifarnib pediatric patient refractory leukemia . - Determine pharmacokinetics drug patient . - Determine toxicity profile drug patient . Secondary - Analyze gene expression profile leukemic blast patient treatment drug . - Determine circulating level nerve growth factor correlate level clinical neurotoxicity drug patient . OUTLINE : This open-label , dose-escalation study . Patients receive oral tipifarnib every 12 hour day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . At least 9 additional patient treat MTD . PROJECTED ACCRUAL : A total 12-34 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphoblastic leukemia , acute nonlymphoblastic leukemia , juvenile myelomonocytic leukemia ( JMML ) , chronic myelogenous leukemia ( CML ) blast crisis Refractory standard curative therapy Acute promyelocytic leukemia refractory tretinoin arsenic trioxide Philadelphia chromosomepositive CML refractory imatinib mesylate Greater 25 % blast bone marrow ( M3 bone marrow ) except patient JMML Active extramedullary disease allow No active leptomeningeal leukemia PATIENT CHARACTERISTICS : Age : 21 Performance status : Karnofsky 50100 % ( 10 year age ) Lansky 50100 % ( 10 year age ) Life expectancy : Not specify Hematopoietic : Not require normal Hepatic : Bilirubin normal SGPT SGOT normal No significant hepatic dysfunction No grade 3 4 liver function test result within past month Renal : Creatinine normal OR Creatinine clearance least 60 mL/min No significant renal dysfunction Cardiovascular : No significant cardiac dysfunction Pulmonary : No significant pulmonary dysfunction Neurologic : No history grand mal seizure grade 3 great except febrile seizures No persistent sensory motor neuropathy great grade 2 Other : No clinically significant unrelated systemic illness No serious infection No organ dysfunction would preclude study participation No requirement total parenteral nutrition No known allergy azoles ( e.g. , clotrimazole , fluconazole , ketoconazole , voriconazole ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior colonystimulating factor therapy ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) except epoetin alfa At least 3 month since prior myeloablative therapy follow bone marrow stem cell transplantation No concurrent immunotherapy No concurrent GMCSF interleukin11 Chemotherapy : At least 2 week since prior chemotherapy No concurrent intrathecal chemotherapy No concurrent chemotherapy Endocrine therapy : At least 1 week since prior corticosteroid No concurrent corticosteroid ( except acute allergic reaction ) Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : Recovered nonhematologic toxicity prior therapy At least 1 week since prior retinoids No antacid ( magnesium aluminumcontaining formulation ) within 2 hour study drug No concurrent investigational agent No concurrent retinoids No concurrent anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
</DOC>